Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 253 to 263 of 263 entries
Sorted by: Best Match Show Resources per page
Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium.

European journal of cancer (Oxford, England : 1990)

de Joode K, Tol J, Hamberg P, Cloos M, Kastelijn EA, Borgers JSW, Nuij VJAA, Klaver Y, Herder GJM, Mutsaers PGNJ, Dumoulin DW, Oomen-de Hoop E, van Diemen NGJ, Libourel EJ, Geraedts EJ, Bootsma GP, van der Leest CH, Peerdeman AL, Herbschleb KH, Visser OJ, Bloemendal HJ, van Laarhoven HWM, de Vries EGE, Hendriks LEL, Beerepoot LV, Westgeest HM, van den Berkmortel FWPJ, Haanen JBAG, Dingemans AC, van der Veldt AAM.
PMID: 34799210
Eur J Cancer. 2021 Oct 25; doi: 10.1016/j.ejca.2021.10.009. Epub 2021 Oct 25.

AIM OF THE STUDY: The coronavirus disease 2019 (COVID-19) pandemic significantly impacted cancer care. In this study, clinical patient characteristics related to COVID-19 outcomes and advanced care planning, in terms of non-oncological treatment restrictions (e.g. do-not-resuscitate codes), were studied...

Cite
de Joode K, Tol J, Hamberg P, et al. Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium. Eur J Cancer. 2021;doi: 10.1016/j.ejca.2021.10.009.
de Joode, K., Tol, J., Hamberg, P., Cloos, M., Kastelijn, E. A., Borgers, J. S. W., Nuij, V. J. A. A., Klaver, Y., Herder, G. J. M., Mutsaers, P. G. N. J., Dumoulin, D. W., Oomen-de Hoop, E., van Diemen, N. G. J., Libourel, E. J., Geraedts, E. J., Bootsma, G. P., van der Leest, C. H., Peerdeman, A. L., Herbschleb, K. H., Visser, O. J., Bloemendal, H. J., van Laarhoven, H. W. M., de Vries, E. G. E., Hendriks, L. E. L., Beerepoot, L. V., Westgeest, H. M., van den Berkmortel, F. W. P. J., Haanen, J. B. A. G., Dingemans, A. C., van der Veldt, A. A. M. (2021). Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium. European journal of cancer (Oxford, England : 1990), . https://doi.org/10.1016/j.ejca.2021.10.009
de Joode, Karlijn, et al. "Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium." European journal of cancer (Oxford, England : 1990) vol. (2021). doi: https://doi.org/10.1016/j.ejca.2021.10.009
de Joode K, Tol J, Hamberg P, Cloos M, Kastelijn EA, Borgers JSW, Nuij VJAA, Klaver Y, Herder GJM, Mutsaers PGNJ, Dumoulin DW, Oomen-de Hoop E, van Diemen NGJ, Libourel EJ, Geraedts EJ, Bootsma GP, van der Leest CH, Peerdeman AL, Herbschleb KH, Visser OJ, Bloemendal HJ, van Laarhoven HWM, de Vries EGE, Hendriks LEL, Beerepoot LV, Westgeest HM, van den Berkmortel FWPJ, Haanen JBAG, Dingemans AC, van der Veldt AAM. Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium. Eur J Cancer. 2021 Oct 25; doi: 10.1016/j.ejca.2021.10.009. Epub 2021 Oct 25. PMID: 34799210; PMCID: PMC8542445.
Copy Download .nbib Format: NLM
Sex-Dependent Shared and Nonshared Genetic Architecture Across Mood and Psychotic Disorders.

Biological psychiatry

Blokland GAM, Grove J, Chen CY, Cotsapas C, Tobet S, Handa R, St Clair D, Lencz T, Mowry BJ, Periyasamy S, Cairns MJ, Tooney PA, Wu JQ, Kelly B, Kirov G, Sullivan PF, Corvin A, Riley BP, Esko T, Milani L, Jönsson EG, Palotie A, Ehrenreich H, Begemann M, Steixner-Kumar A, Sham PC, Iwata N, Weinberger DR, Gejman PV, Sanders AR, Buxbaum JD, Rujescu D, Giegling I, Konte B, Hartmann AM, Bramon E, Murray RM, Pato MT, Lee J, Melle I, Molden E, Ophoff RA, McQuillin A, Bass NJ, Adolfsson R, Malhotra AK, Martin NG, Fullerton JM, Mitchell PB, Schofield PR, Forstner AJ, Degenhardt F, Schaupp S, Comes AL, Kogevinas M, Guzman-Parra J, Reif A, Streit F, Sirignano L, Cichon S, Grigoroiu-Serbanescu M, Hauser J, Lissowska J, Mayoral F, Müller-Myhsok B, Świątkowska B, Schulze TG, Nöthen MM, Rietschel M, Kelsoe J, Leboyer M, Jamain S, Etain B, Bellivier F, Vincent JB, Alda M, O'Donovan C, Cervantes P, Biernacka JM, Frye M, McElroy SL, Scott LJ, Stahl EA, Landén M, Hamshere ML, Smeland OB, Djurovic S, Vaaler AE, Andreassen OA, Baune BT, Air T, Preisig M, Uher R, Levinson DF, Weissman MM, Potash JB, Shi J, Knowles JA, Perlis RH, Lucae S, Boomsma DI, Penninx BWJH, Hottenga JJ, de Geus EJC, Willemsen G, Milaneschi Y, Tiemeier H, Grabe HJ, Teumer A, Van der Auwera S, Völker U, Hamilton SP, Magnusson PKE, Viktorin A, Mehta D, Mullins N, Adams MJ, Breen G, McIntosh AM, Lewis CM, Hougaard DM, Nordentoft M, Mors O, Mortensen PB, Werge T, Als TD, Børglum AD, Petryshen TL, Smoller JW, Goldstein JM.
PMID: 34099189
Biol Psychiatry. 2022 Jan 01;91(1):102-117. doi: 10.1016/j.biopsych.2021.02.972. Epub 2021 Mar 23.

BACKGROUND: Sex differences in incidence and/or presentation of schizophrenia (SCZ), major depressive disorder (MDD), and bipolar disorder (BIP) are pervasive. Previous evidence for shared genetic risk and sex differences in brain abnormalities across disorders suggest possible shared sex-dependent genetic...

Cite
Blokland GAM, Grove J, Chen CY, et al. Sex-Dependent Shared and Nonshared Genetic Architecture Across Mood and Psychotic Disorders. Biol Psychiatry. 2021;91(1):102-117doi: 10.1016/j.biopsych.2021.02.972.
Blokland, G. A. M., Grove, J., Chen, C. Y., Cotsapas, C., Tobet, S., Handa, R., St Clair, D., Lencz, T., Mowry, B. J., Periyasamy, S., Cairns, M. J., Tooney, P. A., Wu, J. Q., Kelly, B., Kirov, G., Sullivan, P. F., Corvin, A., Riley, B. P., Esko, T., Milani, L., Jönsson, E. G., Palotie, A., Ehrenreich, H., Begemann, M., Steixner-Kumar, A., Sham, P. C., Iwata, N., Weinberger, D. R., Gejman, P. V., Sanders, A. R., Buxbaum, J. D., Rujescu, D., Giegling, I., Konte, B., Hartmann, A. M., Bramon, E., Murray, R. M., Pato, M. T., Lee, J., Melle, I., Molden, E., Ophoff, R. A., McQuillin, A., Bass, N. J., Adolfsson, R., Malhotra, A. K., Martin, N. G., Fullerton, J. M., Mitchell, P. B., Schofield, P. R., Forstner, A. J., Degenhardt, F., Schaupp, S., Comes, A. L., Kogevinas, M., Guzman-Parra, J., Reif, A., Streit, F., Sirignano, L., Cichon, S., Grigoroiu-Serbanescu, M., Hauser, J., Lissowska, J., Mayoral, F., Müller-Myhsok, B., Świątkowska, B., Schulze, T. G., Nöthen, M. M., Rietschel, M., Kelsoe, J., Leboyer, M., Jamain, S., Etain, B., Bellivier, F., Vincent, J. B., Alda, M., O'Donovan, C., Cervantes, P., Biernacka, J. M., Frye, M., McElroy, S. L., Scott, L. J., Stahl, E. A., Landén, M., Hamshere, M. L., Smeland, O. B., Djurovic, S., Vaaler, A. E., Andreassen, O. A., Baune, B. T., Air, T., Preisig, M., Uher, R., Levinson, D. F., Weissman, M. M., Potash, J. B., Shi, J., Knowles, J. A., Perlis, R. H., Lucae, S., Boomsma, D. I., Penninx, B. W. J. H., Hottenga, J. J., de Geus, E. J. C., Willemsen, G., Milaneschi, Y., Tiemeier, H., Grabe, H. J., Teumer, A., Van der Auwera, S., Völker, U., Hamilton, S. P., Magnusson, P. K. E., Viktorin, A., Mehta, D., Mullins, N., Adams, M. J., Breen, G., McIntosh, A. M., Lewis, C. M., Hougaard, D. M., Nordentoft, M., Mors, O., Mortensen, P. B., Werge, T., Als, T. D., Børglum, A. D., Petryshen, T. L., Smoller, J. W., & Goldstein, J. M. (2022). Sex-Dependent Shared and Nonshared Genetic Architecture Across Mood and Psychotic Disorders. Biological psychiatry, 91(1), 102-117. https://doi.org/10.1016/j.biopsych.2021.02.972
Blokland, Gabriëlla A M, et al. "Sex-Dependent Shared and Nonshared Genetic Architecture Across Mood and Psychotic Disorders." Biological psychiatry vol. 91,1 (2022): 102-117. doi: https://doi.org/10.1016/j.biopsych.2021.02.972
Blokland GAM, Grove J, Chen CY, Cotsapas C, Tobet S, Handa R, St Clair D, Lencz T, Mowry BJ, Periyasamy S, Cairns MJ, Tooney PA, Wu JQ, Kelly B, Kirov G, Sullivan PF, Corvin A, Riley BP, Esko T, Milani L, Jönsson EG, Palotie A, Ehrenreich H, Begemann M, Steixner-Kumar A, Sham PC, Iwata N, Weinberger DR, Gejman PV, Sanders AR, Buxbaum JD, Rujescu D, Giegling I, Konte B, Hartmann AM, Bramon E, Murray RM, Pato MT, Lee J, Melle I, Molden E, Ophoff RA, McQuillin A, Bass NJ, Adolfsson R, Malhotra AK, Martin NG, Fullerton JM, Mitchell PB, Schofield PR, Forstner AJ, Degenhardt F, Schaupp S, Comes AL, Kogevinas M, Guzman-Parra J, Reif A, Streit F, Sirignano L, Cichon S, Grigoroiu-Serbanescu M, Hauser J, Lissowska J, Mayoral F, Müller-Myhsok B, Świątkowska B, Schulze TG, Nöthen MM, Rietschel M, Kelsoe J, Leboyer M, Jamain S, Etain B, Bellivier F, Vincent JB, Alda M, O'Donovan C, Cervantes P, Biernacka JM, Frye M, McElroy SL, Scott LJ, Stahl EA, Landén M, Hamshere ML, Smeland OB, Djurovic S, Vaaler AE, Andreassen OA, Baune BT, Air T, Preisig M, Uher R, Levinson DF, Weissman MM, Potash JB, Shi J, Knowles JA, Perlis RH, Lucae S, Boomsma DI, Penninx BWJH, Hottenga JJ, de Geus EJC, Willemsen G, Milaneschi Y, Tiemeier H, Grabe HJ, Teumer A, Van der Auwera S, Völker U, Hamilton SP, Magnusson PKE, Viktorin A, Mehta D, Mullins N, Adams MJ, Breen G, McIntosh AM, Lewis CM, Hougaard DM, Nordentoft M, Mors O, Mortensen PB, Werge T, Als TD, Børglum AD, Petryshen TL, Smoller JW, Goldstein JM. Sex-Dependent Shared and Nonshared Genetic Architecture Across Mood and Psychotic Disorders. Biol Psychiatry. 2022 Jan 01;91(1):102-117. doi: 10.1016/j.biopsych.2021.02.972. Epub 2021 Mar 23. PMID: 34099189; PMCID: PMC8458480.
Copy Download .nbib Format: NLM
Parotid salivary sodium levels of Sjögren's syndrome patients suggest B-cell mediated epithelial sodium channel disruption.

Clinical and experimental rheumatology

Pringle SA, Berkhof B, van Ginkel M, Liefers S, van der Vegt B, Spijkervet FKL, Bootsma H, Vissink A, Kroese FGM.
PMID: 34665704
Clin Exp Rheumatol. 2021 Oct 14; Epub 2021 Oct 14.

Patients with primary Sjögren's syndrome (SS) suffer widely from lack of saliva production. Here we investigate potential mechanisms underpinning changes in SS patient saliva composition. Sodium concentration was significantly higher in all saliva samples collected: unstimulated submandibular/sublingual (SmSl) saliva...

Cite
Pringle SA, Berkhof B, van Ginkel M, et al. Parotid salivary sodium levels of Sjögren's syndrome patients suggest B-cell mediated epithelial sodium channel disruption. Clin Exp Rheumatol. 2021;
Pringle, S. A., Berkhof, B., van Ginkel, M., Liefers, S., van der Vegt, B., Spijkervet, F. K. L., Bootsma, H., Vissink, A., & Kroese, F. G. M. (2021). Parotid salivary sodium levels of Sjögren's syndrome patients suggest B-cell mediated epithelial sodium channel disruption. Clinical and experimental rheumatology, .
Pringle, Sarah A, et al. "Parotid salivary sodium levels of Sjögren's syndrome patients suggest B-cell mediated epithelial sodium channel disruption." Clinical and experimental rheumatology vol. (2021).
Pringle SA, Berkhof B, van Ginkel M, Liefers S, van der Vegt B, Spijkervet FKL, Bootsma H, Vissink A, Kroese FGM. Parotid salivary sodium levels of Sjögren's syndrome patients suggest B-cell mediated epithelial sodium channel disruption. Clin Exp Rheumatol. 2021 Oct 14; Epub 2021 Oct 14. PMID: 34665704.
Copy Download .nbib Format: NLM
Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium.

European journal of cancer (Oxford, England : 1990)

de Joode K, Tol J, Hamberg P, Cloos M, Kastelijn EA, Borgers JSW, Nuij VJAA, Klaver Y, Herder GJM, Mutsaers PGNJ, Dumoulin DW, Oomen-de Hoop E, van Diemen NGJ, Libourel EJ, Geraedts EJ, Bootsma GP, van der Leest CH, Peerdeman AL, Herbschleb KH, Visser OJ, Bloemendal HJ, van Laarhoven HWM, de Vries EGE, Hendriks LEL, Beerepoot LV, Westgeest HM, van den Berkmortel FWPJ, Haanen JBAG, Dingemans AC, van der Veldt AAM.
PMID: 34799210
Eur J Cancer. 2022 Jan;160:261-272. doi: 10.1016/j.ejca.2021.10.009. Epub 2021 Oct 25.

AIM OF THE STUDY: The coronavirus disease 2019 (COVID-19) pandemic significantly impacted cancer care. In this study, clinical patient characteristics related to COVID-19 outcomes and advanced care planning, in terms of non-oncological treatment restrictions (e.g. do-not-resuscitate codes), were studied...

Cite
de Joode K, Tol J, Hamberg P, et al. Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium. Eur J Cancer. 2021;160:261-272doi: 10.1016/j.ejca.2021.10.009.
de Joode, K., Tol, J., Hamberg, P., Cloos, M., Kastelijn, E. A., Borgers, J. S. W., Nuij, V. J. A. A., Klaver, Y., Herder, G. J. M., Mutsaers, P. G. N. J., Dumoulin, D. W., Oomen-de Hoop, E., van Diemen, N. G. J., Libourel, E. J., Geraedts, E. J., Bootsma, G. P., van der Leest, C. H., Peerdeman, A. L., Herbschleb, K. H., Visser, O. J., Bloemendal, H. J., van Laarhoven, H. W. M., de Vries, E. G. E., Hendriks, L. E. L., Beerepoot, L. V., Westgeest, H. M., van den Berkmortel, F. W. P. J., Haanen, J. B. A. G., Dingemans, A. C., van der Veldt, A. A. M. (2022). Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium. European journal of cancer (Oxford, England : 1990), 160261-272. https://doi.org/10.1016/j.ejca.2021.10.009
de Joode, Karlijn, et al. "Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium." European journal of cancer (Oxford, England : 1990) vol. 160 (2022): 261-272. doi: https://doi.org/10.1016/j.ejca.2021.10.009
de Joode K, Tol J, Hamberg P, Cloos M, Kastelijn EA, Borgers JSW, Nuij VJAA, Klaver Y, Herder GJM, Mutsaers PGNJ, Dumoulin DW, Oomen-de Hoop E, van Diemen NGJ, Libourel EJ, Geraedts EJ, Bootsma GP, van der Leest CH, Peerdeman AL, Herbschleb KH, Visser OJ, Bloemendal HJ, van Laarhoven HWM, de Vries EGE, Hendriks LEL, Beerepoot LV, Westgeest HM, van den Berkmortel FWPJ, Haanen JBAG, Dingemans AC, van der Veldt AAM. Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium. Eur J Cancer. 2022 Jan;160:261-272. doi: 10.1016/j.ejca.2021.10.009. Epub 2021 Oct 25. PMID: 34799210; PMCID: PMC8542445.
Copy Download .nbib Format: NLM
Undernutrition and sarcopenic obesity: underrecognised conditions in patients with Sjögren's syndrome?.

Clinical and experimental rheumatology

Jager-Wittenaar H, Vissink A, Kroese FGM, Bootsma H.
PMID: 34596029
Clin Exp Rheumatol. 2021 Nov-Dec;39(6):20-22. Epub 2021 Sep 29.

No abstract available.

Cite
Jager-Wittenaar H, Vissink A, Kroese FGM, et al. Undernutrition and sarcopenic obesity: underrecognised conditions in patients with Sjögren's syndrome?. Clin Exp Rheumatol. 2021;39(6):20-22
Jager-Wittenaar, H., Vissink, A., Kroese, F. G. M., & Bootsma, H. (2021). Undernutrition and sarcopenic obesity: underrecognised conditions in patients with Sjögren's syndrome?. Clinical and experimental rheumatology, 39(6), 20-22.
Jager-Wittenaar, Harriët, et al. "Undernutrition and sarcopenic obesity: underrecognised conditions in patients with Sjögren's syndrome?." Clinical and experimental rheumatology vol. 39,6 (2021): 20-22.
Jager-Wittenaar H, Vissink A, Kroese FGM, Bootsma H. Undernutrition and sarcopenic obesity: underrecognised conditions in patients with Sjögren's syndrome?. Clin Exp Rheumatol. 2021 Nov-Dec;39(6):20-22. Epub 2021 Sep 29. PMID: 34596029.
Copy Download .nbib Format: NLM
Practical guidelines for the early diagnosis of Sjögren's syndrome in primary healthcare.

Clinical and experimental rheumatology

Sisó-Almirall A, Meijer JM, Brito-Zerón P, Conangla L, Flores-Chavez A, González de Paz L, Bootsma H, Ramos-Casals M.
PMID: 34874832
Clin Exp Rheumatol. 2021 Nov-Dec;39(6):197-205. Epub 2021 Nov 29.

Primary care physicians can play a crucial role by recognising Sjögren's syndrome (SS) in the early stages identifying those patients with the greatest probability of being diagnosed with SS. SS has a very specific epidemiological profile at presentation (female...

Cite
Sisó-Almirall A, Meijer JM, Brito-Zerón P, et al. Practical guidelines for the early diagnosis of Sjögren's syndrome in primary healthcare. Clin Exp Rheumatol. 2021;39(6):197-205
Sisó-Almirall, A., Meijer, J. M., Brito-Zerón, P., Conangla, L., Flores-Chavez, A., González de Paz, L., Bootsma, H., & Ramos-Casals, M. (2021). Practical guidelines for the early diagnosis of Sjögren's syndrome in primary healthcare. Clinical and experimental rheumatology, 39(6), 197-205.
Sisó-Almirall, Antoni, et al. "Practical guidelines for the early diagnosis of Sjögren's syndrome in primary healthcare." Clinical and experimental rheumatology vol. 39,6 (2021): 197-205.
Sisó-Almirall A, Meijer JM, Brito-Zerón P, Conangla L, Flores-Chavez A, González de Paz L, Bootsma H, Ramos-Casals M. Practical guidelines for the early diagnosis of Sjögren's syndrome in primary healthcare. Clin Exp Rheumatol. 2021 Nov-Dec;39(6):197-205. Epub 2021 Nov 29. PMID: 34874832.
Copy Download .nbib Format: NLM
Predicting cancer drug TARGETS - TreAtment Response Generalized Elastic-neT Signatures.

NPJ genomic medicine

Rydzewski NR, Peterson E, Lang JM, Yu M, Laura Chang S, Sjöström M, Bakhtiar H, Song G, Helzer KT, Bootsma ML, Chen WS, Shrestha RM, Zhang M, Quigley DA, Aggarwal R, Small EJ, Wahl DR, Feng FY, Zhao SG.
PMID: 34548481
NPJ Genom Med. 2021 Sep 21;6(1):76. doi: 10.1038/s41525-021-00239-z.

We are now in an era of molecular medicine, where specific DNA alterations can be used to identify patients who will respond to specific drugs. However, there are only a handful of clinically used predictive biomarkers in oncology. Herein,...

Cite
Rydzewski NR, Peterson E, Lang JM, et al. Predicting cancer drug TARGETS - TreAtment Response Generalized Elastic-neT Signatures. NPJ Genom Med. 2021;6(1):76doi: 10.1038/s41525-021-00239-z.
Rydzewski, N. R., Peterson, E., Lang, J. M., Yu, M., Laura Chang, S., Sjöström, M., Bakhtiar, H., Song, G., Helzer, K. T., Bootsma, M. L., Chen, W. S., Shrestha, R. M., Zhang, M., Quigley, D. A., Aggarwal, R., Small, E. J., Wahl, D. R., Feng, F. Y., & Zhao, S. G. (2021). Predicting cancer drug TARGETS - TreAtment Response Generalized Elastic-neT Signatures. NPJ genomic medicine, 6(1), 76. https://doi.org/10.1038/s41525-021-00239-z
Rydzewski, Nicholas R, et al. "Predicting cancer drug TARGETS - TreAtment Response Generalized Elastic-neT Signatures." NPJ genomic medicine vol. 6,1 (2021): 76. doi: https://doi.org/10.1038/s41525-021-00239-z
Rydzewski NR, Peterson E, Lang JM, Yu M, Laura Chang S, Sjöström M, Bakhtiar H, Song G, Helzer KT, Bootsma ML, Chen WS, Shrestha RM, Zhang M, Quigley DA, Aggarwal R, Small EJ, Wahl DR, Feng FY, Zhao SG. Predicting cancer drug TARGETS - TreAtment Response Generalized Elastic-neT Signatures. NPJ Genom Med. 2021 Sep 21;6(1):76. doi: 10.1038/s41525-021-00239-z. PMID: 34548481; PMCID: PMC8455625.
Copy Download .nbib Format: NLM
Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium.

European journal of cancer (Oxford, England : 1990)

de Joode K, Tol J, Hamberg P, Cloos M, Kastelijn EA, Borgers JSW, Nuij VJAA, Klaver Y, Herder GJM, Mutsaers PGNJ, Dumoulin DW, Oomen-de Hoop E, van Diemen NGJ, Libourel EJ, Geraedts EJ, Bootsma GP, van der Leest CH, Peerdeman AL, Herbschleb KH, Visser OJ, Bloemendal HJ, van Laarhoven HWM, de Vries EGE, Hendriks LEL, Beerepoot LV, Westgeest HM, van den Berkmortel FWPJ, Haanen JBAG, Dingemans AC, van der Veldt AAM.
PMID: 34799210
Eur J Cancer. 2022 Jan;160:261-272. doi: 10.1016/j.ejca.2021.10.009. Epub 2021 Oct 25.

AIM OF THE STUDY: The coronavirus disease 2019 (COVID-19) pandemic significantly impacted cancer care. In this study, clinical patient characteristics related to COVID-19 outcomes and advanced care planning, in terms of non-oncological treatment restrictions (e.g. do-not-resuscitate codes), were studied...

Cite
de Joode K, Tol J, Hamberg P, et al. Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium. Eur J Cancer. 2021;160:261-272doi: 10.1016/j.ejca.2021.10.009.
de Joode, K., Tol, J., Hamberg, P., Cloos, M., Kastelijn, E. A., Borgers, J. S. W., Nuij, V. J. A. A., Klaver, Y., Herder, G. J. M., Mutsaers, P. G. N. J., Dumoulin, D. W., Oomen-de Hoop, E., van Diemen, N. G. J., Libourel, E. J., Geraedts, E. J., Bootsma, G. P., van der Leest, C. H., Peerdeman, A. L., Herbschleb, K. H., Visser, O. J., Bloemendal, H. J., van Laarhoven, H. W. M., de Vries, E. G. E., Hendriks, L. E. L., Beerepoot, L. V., Westgeest, H. M., van den Berkmortel, F. W. P. J., Haanen, J. B. A. G., Dingemans, A. C., van der Veldt, A. A. M. (2022). Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium. European journal of cancer (Oxford, England : 1990), 160261-272. https://doi.org/10.1016/j.ejca.2021.10.009
de Joode, Karlijn, et al. "Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium." European journal of cancer (Oxford, England : 1990) vol. 160 (2022): 261-272. doi: https://doi.org/10.1016/j.ejca.2021.10.009
de Joode K, Tol J, Hamberg P, Cloos M, Kastelijn EA, Borgers JSW, Nuij VJAA, Klaver Y, Herder GJM, Mutsaers PGNJ, Dumoulin DW, Oomen-de Hoop E, van Diemen NGJ, Libourel EJ, Geraedts EJ, Bootsma GP, van der Leest CH, Peerdeman AL, Herbschleb KH, Visser OJ, Bloemendal HJ, van Laarhoven HWM, de Vries EGE, Hendriks LEL, Beerepoot LV, Westgeest HM, van den Berkmortel FWPJ, Haanen JBAG, Dingemans AC, van der Veldt AAM. Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium. Eur J Cancer. 2022 Jan;160:261-272. doi: 10.1016/j.ejca.2021.10.009. Epub 2021 Oct 25. PMID: 34799210; PMCID: PMC8542445.
Copy Download .nbib Format: NLM
Enhancing perioperative landmark detection during sacroiliac joint fusion in patients suffering from low back pain.

Computer assisted surgery (Abingdon, England)

Schippers B, Hekman E, van Helden S, Boomsma M, van Osch J, Nijveldt R.
PMID: 33941011
Comput Assist Surg (Abingdon). 2021 Dec;26(1):41-48. doi: 10.1080/24699322.2021.1916600.

Over the past decade, minimally invasive sacroiliac joint (SIJ) fusion has become an effective treatment for patients suffering from low back pain (LBP) originating from the SIJ. Perioperative C-arm fluoroscopy-assisted surgical navigation during SIJ fusion remains challenging due to...

Cite
Schippers B, Hekman E, van Helden S, et al. Enhancing perioperative landmark detection during sacroiliac joint fusion in patients suffering from low back pain. Comput Assist Surg (Abingdon). 2021;26(1):41-48doi: 10.1080/24699322.2021.1916600.
Schippers, B., Hekman, E., van Helden, S., Boomsma, M., van Osch, J., & Nijveldt, R. (2021). Enhancing perioperative landmark detection during sacroiliac joint fusion in patients suffering from low back pain. Computer assisted surgery (Abingdon, England), 26(1), 41-48. https://doi.org/10.1080/24699322.2021.1916600
Schippers, Bas, et al. "Enhancing perioperative landmark detection during sacroiliac joint fusion in patients suffering from low back pain." Computer assisted surgery (Abingdon, England) vol. 26,1 (2021): 41-48. doi: https://doi.org/10.1080/24699322.2021.1916600
Schippers B, Hekman E, van Helden S, Boomsma M, van Osch J, Nijveldt R. Enhancing perioperative landmark detection during sacroiliac joint fusion in patients suffering from low back pain. Comput Assist Surg (Abingdon). 2021 Dec;26(1):41-48. doi: 10.1080/24699322.2021.1916600. PMID: 33941011.
Copy Download .nbib Format: NLM
Item-Level Genome-Wide Association Study of the Alcohol Use Disorders Identification Test in Three Population-Based Cohorts.

The American journal of psychiatry

Mallard TT, Savage JE, Johnson EC, Huang Y, Edwards AC, Hottenga JJ, Grotzinger AD, Gustavson DE, Jennings MV, Anokhin A, Dick DM, Edenberg HJ, Kramer JR, Lai D, Meyers JL, Pandey AK, Harden KP, Nivard MG, de Geus EJC, Boomsma DI, Agrawal A, Davis LK, Clarke TK, Palmer AA, Sanchez-Roige S.
PMID: 33985350
Am J Psychiatry. 2021 May 14;appiajp202020091390. doi: 10.1176/appi.ajp.2020.20091390. Epub 2021 May 14.

OBJECTIVE: Genome-wide association studies (GWASs) of the Alcohol Use Disorders Identification Test (AUDIT), a 10-item screen for alcohol use disorder (AUD), have elucidated novel loci for alcohol consumption and misuse. However, these studies also revealed that GWASs can be...

Cite
Mallard TT, Savage JE, Johnson EC, et al. Item-Level Genome-Wide Association Study of the Alcohol Use Disorders Identification Test in Three Population-Based Cohorts. Am J Psychiatry. 2021;appiajp202020091390doi: 10.1176/appi.ajp.2020.20091390.
Mallard, T. T., Savage, J. E., Johnson, E. C., Huang, Y., Edwards, A. C., Hottenga, J. J., Grotzinger, A. D., Gustavson, D. E., Jennings, M. V., Anokhin, A., Dick, D. M., Edenberg, H. J., Kramer, J. R., Lai, D., Meyers, J. L., Pandey, A. K., Harden, K. P., Nivard, M. G., de Geus, E. J. C., Boomsma, D. I., Agrawal, A., Davis, L. K., Clarke, T. K., Palmer, A. A., & Sanchez-Roige, S. (2021). Item-Level Genome-Wide Association Study of the Alcohol Use Disorders Identification Test in Three Population-Based Cohorts. The American journal of psychiatry, appiajp202020091390. https://doi.org/10.1176/appi.ajp.2020.20091390
Mallard, Travis T, et al. "Item-Level Genome-Wide Association Study of the Alcohol Use Disorders Identification Test in Three Population-Based Cohorts." The American journal of psychiatry vol. (2021): appiajp202020091390. doi: https://doi.org/10.1176/appi.ajp.2020.20091390
Mallard TT, Savage JE, Johnson EC, Huang Y, Edwards AC, Hottenga JJ, Grotzinger AD, Gustavson DE, Jennings MV, Anokhin A, Dick DM, Edenberg HJ, Kramer JR, Lai D, Meyers JL, Pandey AK, Harden KP, Nivard MG, de Geus EJC, Boomsma DI, Agrawal A, Davis LK, Clarke TK, Palmer AA, Sanchez-Roige S. Item-Level Genome-Wide Association Study of the Alcohol Use Disorders Identification Test in Three Population-Based Cohorts. Am J Psychiatry. 2021 May 14;appiajp202020091390. doi: 10.1176/appi.ajp.2020.20091390. Epub 2021 May 14. PMID: 33985350.
Copy Download .nbib Format: NLM
UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients.

European journal of cancer (Oxford, England : 1990)

Hulshof EC, de With M, de Man FM, Creemers GJ, Deiman BALM, Swen JJ, Houterman S, Koolen SLW, Bins S, Thijs AMJ, Laven MMJ, Hövels AM, Luelmo SAC, Houtsma D, Shulman K, McLeod HL, van Schaik RHN, Guchelaar HJ, Mathijssen RHJ, Gelderblom H, Deenen MJ.
PMID: 34998046
Eur J Cancer. 2022 Jan 05;162:148-157. doi: 10.1016/j.ejca.2021.12.009. Epub 2022 Jan 05.

AIM: To determine the safety, feasibility, pharmacokinetics, and cost of UGT1A1 genotype-guided dosing of irinotecan.PATIENTS AND METHODS: In this prospective, multicentre, non-randomised study, patients intended for treatment with irinotecan were pre-therapeutically genotyped for UGT1A1∗28 and UGT1A1∗93. Homozygous variant carriers...

Cite
Hulshof EC, de With M, de Man FM, et al. UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients. Eur J Cancer. 2022;162:148-157doi: 10.1016/j.ejca.2021.12.009.
Hulshof, E. C., de With, M., de Man, F. M., Creemers, G. J., Deiman, B. A. L. M., Swen, J. J., Houterman, S., Koolen, S. L. W., Bins, S., Thijs, A. M. J., Laven, M. M. J., Hövels, A. M., Luelmo, S. A. C., Houtsma, D., Shulman, K., McLeod, H. L., van Schaik, R. H. N., Guchelaar, H. J., Mathijssen, R. H. J., Gelderblom, H., & Deenen, M. J. (2022). UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients. European journal of cancer (Oxford, England : 1990), 162148-157. https://doi.org/10.1016/j.ejca.2021.12.009
Hulshof, Emma C, et al. "UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients." European journal of cancer (Oxford, England : 1990) vol. 162 (2022): 148-157. doi: https://doi.org/10.1016/j.ejca.2021.12.009
Hulshof EC, de With M, de Man FM, Creemers GJ, Deiman BALM, Swen JJ, Houterman S, Koolen SLW, Bins S, Thijs AMJ, Laven MMJ, Hövels AM, Luelmo SAC, Houtsma D, Shulman K, McLeod HL, van Schaik RHN, Guchelaar HJ, Mathijssen RHJ, Gelderblom H, Deenen MJ. UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients. Eur J Cancer. 2022 Jan 05;162:148-157. doi: 10.1016/j.ejca.2021.12.009. Epub 2022 Jan 05. PMID: 34998046.
Copy Download .nbib Format: NLM
Showing 253 to 263 of 263 entries